The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).
 
Phillip Lee Palmbos
No Relationships to Disclose
 
Scott A. Tomlins
Leadership - Strata Oncology
Stock and Other Ownership Interests - Strata Oncology
Consulting or Advisory Role - Abbvie; Almac Diagnostics; Astellas Medivation; Janssen; Roche; Sanofi; Strata Oncology; Ventana Medical Systems
Research Funding - Astellas Medivation (Inst); Compendia Bioscience (Inst); GenomeDx (Inst); Life Technologies (Inst); Thermo Fisher Scientific (Inst)
Patents, Royalties, Other Intellectual Property - I am a coauthor on a patent issued to the University of Michigan on ETS gene fusions in prostate cancer. The diagnostic field of use has been licensed to Hologic/Gen-Probe Inc., who has sublicensed some rights to Ventana Medical Systems/Roche.
Travel, Accommodations, Expenses - Compendia Bioscience; Life Technologies; Strata Oncology; Thermo Fisher Scientific
 
Neeraj Agarwal
Consulting or Advisory Role - Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Przemyslaw Twardowski
No Relationships to Disclose
 
Alicia K. Morgans
Honoraria - AstraZeneca; Genentech; Janssen; Johnson & Johnson; Sanofi
Consulting or Advisory Role - AstraZeneca; Genentech; Sanofi
Travel, Accommodations, Expenses - Genentech
 
William Kevin Kelly
Consulting or Advisory Role - Sanofi
Research Funding - Janssen Oncology (Inst); Novartis (Inst); Sanofi (Inst)
Other Relationship - Sanofi
 
Vivek Arora
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi
 
Javed Siddiqui
No Relationships to Disclose
 
Stephanie Daignault
No Relationships to Disclose
 
Karen E. Knudsen
Honoraria - Celgene; CellCentric
Consulting or Advisory Role - CellCentric
Research Funding - Celgene; Sanofi
 
Felix Y Feng
Leadership - PFS Genomics
Stock and Other Ownership Interests - PFS Genomics
Consulting or Advisory Role - Celgene; Dendreon; EMD Serono; Ferring; GenomeDx; Janssen Oncology; Medivation/Astellas; Sanofi
Research Funding - Celgene; Varian Medical Systems
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst)
 
Maha Hussain
Honoraria - Onclive; Sanofi
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi